It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals (NASDAQ: RXRX). Earlier this year, the company's shares skyrocketed after it announced a partnership with the tech giant Nvidia, but Recursion has since given up all these gains -- and then some. As of this writing, the company's stock is down by 8% since the year started.

Still, Recursion has a bold project in place (more on that below), and if it pans out, the company could deliver outsize returns to its shareholders. Does that make Recursion Pharmaceuticals' shares a buy today?

Continue reading

Source Fool.com